Artelo Biosciences Reports Q3 2026 Financial Results
Artelo Biosciences reported a Q3 2026 net loss of $1.8 million or $3.19 per basic and diluted common share, compared to a net loss of $3.1 million in Q3 2025. R&D expenses decreased to $0.8 million from $1.3 million year-over-year, while G&A expenses declined to $1.0 million from $1.8 million. The company ended the quarter with $4.4 million in cash.
Key takeaways
Q3 2026 net loss was $1.8 million compared to $3.1 million in Q3 2025, a reduction in loss of $1.3 million.
R&D expenses decreased to $0.8 million in Q3 2026 from $1.3 million in Q3 2025.
G&A expenses declined to $1.0 million in Q3 2026 from $1.8 million in Q3 2025.
Cash and investments totaled $4.4 million as of September 30, 2026.
ART27.13 demonstrated approximately 20% weight loss as monotherapy and 40% weight loss when combined with semaglutide in diet-induced obesity animal model.
Phase 2 DREAM trial initiated for ART27.13 in glaucoma with enrollment underway.
Phase 1 MAD study for ART26.12 planned to initiate in Q4 2026.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow ARTL in real time
Get material earnings, filing, IR, and earnings-call alerts by email.